Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Notes Payables (2016 - 2025)

Vistagen Therapeutics' Notes Payables history spans 10 years, with the latest figure at $400000.0 for Q4 2025.

  • For Q4 2025, Notes Payables changed N/A year-over-year to $400000.0; the TTM value through Dec 2025 reached $400000.0, changed N/A, while the annual FY2020 figure was $56500.0, N/A changed from the prior year.
  • Notes Payables for Q4 2025 was $400000.0 at Vistagen Therapeutics, down from $700000.0 in the prior quarter.
  • Across five years, Notes Payables topped out at $933000.0 in Q2 2025 and bottomed at $400000.0 in Q4 2025.